Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL
Combining CAR-T therapy with a targeted drug achieves strong responses in hard-to-treat blood cancers, offering a promising two-pronged approach for patients who've exhausted other options.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Tumor-induced dendritic cell deregulation perturbs T cell…
Identifying why tumor cells suppress immune cells opens a door to reversing this sabotage and strengthening the body's natural cancer-fighting defenses in leukemia.
Promising but preliminaryHaematological pre-staging of colorectal cancer
Routine blood test patterns detected up to two years before colorectal cancer diagnosis could flag high-risk patients for earlier screening and intervention.
Promising but preliminaryDevelopment and Multi-center Validation of a Breathomics-Based Triage…
A breath test successfully identified lung cancer with 93% sensitivity in nearly 550 patients, suggesting a simple, non-invasive screening tool may soon help catch disease earlier.
Early cancer detection or preventionAssociations between early changes in circulating tumor DNA (ctDNA)…
When circulating tumor DNA drops sharply after treatment, patients survive significantly longer—validating this blood marker as a practical early signal of how well cancer therapy is working.